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WST11 vascular targeted photodynamic therapy (VTP) is a local ablation approach
relying upon rapid, free radical-mediated destruction of tumor vasculature. A phase
III trial showed that VTP significantly reduced disease progression when compared
with active surveillance in patients with low-risk prostate cancer. The aim of this
study was to identify a druggable pathway that could be combined with VTP to
improve its efficacy and applicability to higher risk prostate cancer tumors.
Transcriptome analysis of VTP-treated tumors (LNCaP-AR xenografts) was used to
identify a candidate pathway for combination therapy. The efficacy of the
combination therapy was assessed in mice bearing LNCaP-AR or VCaP tumors. Gene
set enrichment analysis identifies the enrichment of androgen-responsive gene sets
within hours after VTP treatment, suggesting that the androgen receptor (AR) may
be a viable target in combination with VTP. We tested this hypothesis in mice bearing
LNCaP-AR xenograft tumors by using androgen deprivation therapy (ADT), degarelix,
in combination with VTP. Compared with either ADT or VTP alone, a single dose of
degarelix in concert with VTP significantly inhibited tumor growth. A sharp decline in
serum prostate-specific antigen (PSA) confirmed AR inhibition in this group. Tumors
treated by VTP and degarelix displayed intense terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling staining 7 days after treatment,
supporting an increased apoptotic frequency underlying the effect on tumor
inhibition. Improvement of local tumor control following androgen deprivation
combined with VTP provides the rationale and preliminary protocol parameters for
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